It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark.
Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting
CSL Behring’s haemophilia B gene therapy Hemgenix has become the first drug to be authorised for use under France’s recently-introduced ‘direct access’ programme, which ai
CSL Behring's recently approved gene therapy for haemophilia B Hemgenix has joined the swelling ranks of new medicines that are bundled with a companion app to support the
The UK's National Institute for Health and Care Excellence (NICE) has said it is minded not to recommend approval of CSL Behring and uniQure's Hemgenix gene therapy for ha
CSL's gene therapy for haemophilia B has been recommended for approval by the EMA's human medicine committee, setting up a decision by the European Commission early next year.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.